Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stock fluctuated after announcing positive Phase 2 RADIANT study results for vormatrigine in epilepsy patients. The stock initially surged but is now down 9%. The study included data from 37 patients, showing a median seizure reduction of 56.3% and 60% achieving at least a 50% reduction.

In an investor presentation, Praxis highlighted that 54% of patients achieved a 50% seizure reduction in Week 1, 67% in Week 8, and 22% experienced a 100% reduction in the last month. Most adverse events were mild to moderate, with all severe events resolving. The company plans to complete the POWER1 study by Q4 2025.

Praxis reported cash and investments of $447 million, with a cash runway into 2028. In July, the FDA granted Breakthrough Therapy Designation for relutrigine in pediatric epilepsy. The EMBOLD trial expects to release topline results in H1 2026, with an NDA filing to follow. The company has initiated the EMERALD study on relutrigine for DEEs.

PRAX stock is currently trading at $48.95, down 9.51%. Praxis continues to make strides in epilepsy treatment, with promising results from its studies.

Read more at Yahoo Finance: Praxis’ Epilepsy Treatment Shows Promise With Decreased Seizures